LAWRENCEVILLE, NJ--(MARKET WIRE)--Aug 2, 2007 -- Healthcare Providers Direct, Inc. (OTC BB:HPRD.OB - News), an early-stage company focused on the development and distribution of rapid diagnostic tests directly to physicians’ offices, announced today that it plans to begin clinical studies on a new diagnostic test for Chlamydia in an effort to secure FDA 510(k) pre-market approval. The clinical study for the Chlamydia test is set to begin August 13th, 2007 at three different geographical sites in the U.S. A 510(k) application is the official document that is submitted to the Food and Drug Administration when seeking pre-market approval for products that aid physicians in the diagnosis and treatment of disease conditions.
